Cue Biopharma (CUE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CUE Stock Forecast

Cue Biopharma stock forecast is as follows: an average price target of $3.00 (represents a 197.03% upside from CUE’s last price of $1.01) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CUE Price Target

The average price target for Cue Biopharma (CUE) is $3.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $2.00. This represents a potential 197.03% upside from CUE's last price of $1.01.

CUE Analyst Ratings

Buy

According to 3 Wall Street analysts, Cue Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for CUE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cue Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 15, 2024	Maury Raycroft	Jefferies	$4.00	$1.28	211.28%	296.04%
Jul 26, 2024	Reni Benjamin	JMP Securities	$2.00	$0.70	184.37%	98.02%
Mar 13, 2024	Maury Raycroft	Jefferies	$6.00	$2.15	179.07%	494.06%
Nov 20, 2022	Edward Tenthoff	Piper Sandler	$7.00	$3.22	117.39%	593.07%

The latest Cue Biopharma stock forecast, released on Nov 15, 2024 by Maury Raycroft from Jefferies, set a price target of $4.00, which represents a 211.28% increase from the stock price at the time of the forecast ($1.28), and a 296.04% increase from CUE last price ($1.01).

Cue Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	3
Avg Price Target	-	$4.00	$4.00
Last Closing Price	$1.01	$1.01	$1.01
Upside/Downside	-100.00%	296.04%	296.04%

In the current month, the average price target of Cue Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cue Biopharma's last price of $1.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 15, 2024	Jefferies	Buy	Buy	Hold
Jul 26, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 26, 2024	JMP Securities	Outperform	Outperform	Hold
Apr 09, 2024	Oppenheimer	Underperform	Underperform	Hold
Apr 09, 2024	Piper Sandler	Buy	Buy	Hold
Nov 20, 2022	Piper Sandler		Overweight	Initialise

Cue Biopharma's last stock rating was published by Jefferies on Nov 15, 2024. The company gave CUE a "Buy" rating, the same as its previous rate.

Cue Biopharma Financial Forecast

Cue Biopharma Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Revenue	-	-	-	-	-	-	-	-	-	-	$1.38M	$187.00K	$151.23K	$68.00K	$26.00K	$1.00M	$1.57M	$2.40M	$2.74M	$1.55M	$475.32K	$704.00K	$1.07M	$900.00K	$1.05M	$984.00K	$1.05M	$370.00K	$449.00K
Avg Forecast	$1.89M	$1.83M	$1.60M	$1.27M	$1.70M	$1.52M	$1.29M	$1.21M	$966.67K	$1.31M	$907.50K	$1.95M	$103.75K	$513.50K	$1.13M	$3.05M	$1.14M	$2.40M	$1.06M	$585.60K	$1.49M	$1.27M	$930.00K	$1.36M	$836.00K	$225.00K	$225.00K	$225.00K	$275.19K
High Forecast	$1.89M	$1.83M	$1.60M	$1.27M	$2.24M	$1.52M	$1.29M	$1.21M	$2.08M	$1.31M	$907.50K	$1.95M	$103.75K	$513.50K	$1.13M	$3.05M	$1.14M	$2.40M	$1.06M	$585.60K	$1.49M	$1.27M	$930.00K	$1.36M	$836.00K	$225.00K	$225.00K	$225.00K	$330.23K
Low Forecast	$1.89M	$1.83M	$1.60M	$1.27M	$1.02M	$1.52M	$1.29M	$1.21M	$68.56K	$1.31M	$907.50K	$1.95M	$103.75K	$513.50K	$1.13M	$3.05M	$1.14M	$2.40M	$1.06M	$585.60K	$1.49M	$1.27M	$930.00K	$1.36M	$836.00K	$225.00K	$225.00K	$225.00K	$220.15K
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	13	13	7	7	9	8	6	10	6	14
Surprise %	-	-	-	-	-	-	-	-	-	-	1.52%	0.10%	1.46%	0.13%	0.02%	0.33%	1.38%	1.00%	2.59%	2.65%	0.32%	0.55%	1.16%	0.66%	1.26%	4.37%	4.69%	1.64%	1.63%

Cue Biopharma's average Quarter revenue forecast for Sep 23 based on 2 analysts is $1.31M, with a low forecast of $1.31M, and a high forecast of $1.31M. CUE's average Quarter revenue forecast represents a -5.39% decrease compared to the company's last Quarter revenue of $1.38M (Jun 23).

Cue Biopharma EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	13	13	7	7	9	8	6	10	6	14
EBITDA	-	-	-	-	-	-	-	-	-	-	$-12.10M	$-11.86M	$-13.67M	$-10.29M	$-12.88M	$-13.93M	$-7.58M	$-12.68M	$-9.96M	$-12.19M	$-10.64M	$-9.76M	$-11.56M	$-11.56M	$-7.39M	$-5.77M	$-7.89M	$-10.06M	$-12.37M
Avg Forecast	$-1.89M	$-1.83M	$-1.60M	$-1.27M	$-1.70M	$-1.52M	$-1.29M	$-1.21M	$-966.67K	$-1.31M	$-907.50K	$-1.95M	$-103.75K	$-513.50K	$-1.13M	$-13.60M	$-1.14M	$-2.40M	$-1.06M	$-11.22M	$-1.49M	$-1.27M	$-930.00K	$-7.26M	$-836.00K	$-225.00K	$-225.00K	$-6.54M	$-5.01M
High Forecast	$-1.89M	$-1.83M	$-1.60M	$-1.27M	$-1.02M	$-1.52M	$-1.29M	$-1.21M	$-68.56K	$-1.31M	$-907.50K	$-1.95M	$-103.75K	$-513.50K	$-1.13M	$-10.88M	$-1.14M	$-2.40M	$-1.06M	$-8.98M	$-1.49M	$-1.27M	$-930.00K	$-5.81M	$-836.00K	$-225.00K	$-225.00K	$-5.23M	$-4.01M
Low Forecast	$-1.89M	$-1.83M	$-1.60M	$-1.27M	$-2.24M	$-1.52M	$-1.29M	$-1.21M	$-2.08M	$-1.31M	$-907.50K	$-1.95M	$-103.75K	$-513.50K	$-1.13M	$-16.32M	$-1.14M	$-2.40M	$-1.06M	$-13.47M	$-1.49M	$-1.27M	$-930.00K	$-8.72M	$-836.00K	$-225.00K	$-225.00K	$-7.85M	$-6.01M
Surprise %	-	-	-	-	-	-	-	-	-	-	13.34%	6.08%	131.78%	20.04%	11.38%	1.02%	6.65%	5.29%	9.43%	1.09%	7.15%	7.68%	12.43%	1.59%	8.84%	25.65%	35.08%	1.54%	2.47%

undefined analysts predict CUE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cue Biopharma's previous annual EBITDA (undefined) of $NaN.

Cue Biopharma Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	13	13	7	7	9	8	6	10	6	14
Net Income	-	-	-	-	-	-	-	-	-	-	$-13.19M	$-13.21M	$-14.45M	$-10.88M	$-13.33M	$-14.27M	$-8.39M	$-12.99M	$-10.28M	$-12.51M	$-11.10M	$-10.03M	$-10.83M	$-12.82M	$-8.92M	$-6.99M	$-9.52M	$-11.27M	$-12.56M
Avg Forecast	$-7.00M	$-6.83M	$-7.17M	$-8.03M	$-4.41M	$-9.35M	$-14.34M	$-14.45M	$-15.37M	$-16.65M	$-15.63M	$-14.22M	$-15.11M	$-18.90M	$-19.57M	$-13.92M	$-21.17M	$-19.32M	$-20.92M	$-11.52M	$-17.56M	$-18.26M	$-20.32M	$-8.06M	$-22.45M	$-22.08M	$-23.08M	$-7.32M	$-5.09M
High Forecast	$-7.00M	$-6.83M	$-7.17M	$-6.96M	$-3.30M	$-9.35M	$-14.34M	$-14.45M	$-13.78M	$-16.65M	$-15.63M	$-14.22M	$-15.11M	$-18.90M	$-19.57M	$-11.14M	$-21.17M	$-19.32M	$-20.92M	$-9.21M	$-17.56M	$-18.26M	$-20.32M	$-6.45M	$-22.45M	$-22.08M	$-23.08M	$-5.86M	$-4.07M
Low Forecast	$-7.00M	$-6.83M	$-7.17M	$-9.10M	$-5.78M	$-9.35M	$-14.34M	$-14.45M	$-18.02M	$-16.65M	$-15.63M	$-14.22M	$-15.11M	$-18.90M	$-19.57M	$-16.71M	$-21.17M	$-19.32M	$-20.92M	$-13.82M	$-17.56M	$-18.26M	$-20.32M	$-9.67M	$-22.45M	$-22.08M	$-23.08M	$-8.79M	$-6.11M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.84%	0.93%	0.96%	0.58%	0.68%	1.03%	0.40%	0.67%	0.49%	1.09%	0.63%	0.55%	0.53%	1.59%	0.40%	0.32%	0.41%	1.54%	2.47%

Cue Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CUE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cue Biopharma SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	13	13	7	7	9	8	6	10	6	14
SG&A	-	-	-	-	-	-	-	-	-	-	$4.25M	$4.18M	$3.70M	$3.53M	$3.78M	$5.16M	$4.67M	$4.10M	$4.28M	$4.25M	$3.45M	$3.32M	$3.90M	$3.99M	$3.10M	$2.78M	$3.42M	$3.44M	$2.90M
Avg Forecast	$9.66M	$9.36M	$8.15M	$6.47M	$8.68M	$7.75M	$6.58M	$6.18M	$4.93M	$6.67M	$4.63M	$9.95M	$529.33K	$2.57M	$5.65M	$15.26M	$5.69M	$11.97M	$5.28M	$2.93M	$7.44M	$6.35M	$4.65M	$6.78M	$4.18M	$1.12M	$1.12M	$1.12M	$1.37M
High Forecast	$9.66M	$9.36M	$8.15M	$6.47M	$11.43M	$7.75M	$6.58M	$6.18M	$10.60M	$6.67M	$4.63M	$9.95M	$529.33K	$2.57M	$5.65M	$15.26M	$5.69M	$11.97M	$5.28M	$2.93M	$7.44M	$6.35M	$4.65M	$6.78M	$4.18M	$1.12M	$1.12M	$1.12M	$1.65M
Low Forecast	$9.66M	$9.36M	$8.15M	$6.47M	$5.20M	$7.75M	$6.58M	$6.18M	$349.78K	$6.67M	$4.63M	$9.95M	$529.33K	$2.57M	$5.65M	$15.26M	$5.69M	$11.97M	$5.28M	$2.93M	$7.44M	$6.35M	$4.65M	$6.78M	$4.18M	$1.12M	$1.12M	$1.12M	$1.10M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.92%	0.42%	7.00%	1.38%	0.67%	0.34%	0.82%	0.34%	0.81%	1.45%	0.46%	0.52%	0.84%	0.59%	0.74%	2.47%	3.04%	3.06%	2.11%

Cue Biopharma's average Quarter SG&A projection for Sep 23 is $6.67M, based on 2 Wall Street analysts, with a range of $6.67M to $6.67M. The forecast indicates a 57.00% rise compared to CUE last annual SG&A of $4.25M (Jun 23).

Cue Biopharma EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	13	13	7	7	9	8	6	10	6	14
EPS	-	-	-	-	-	-	-	-	-	-	$-0.29	$-0.30	$-0.41	$-0.31	$-0.38	$-0.44	$-0.27	$-0.41	$-0.33	$-0.41	$-0.37	$-0.34	$-0.38	$-0.48	$-0.37	$-0.31	$-0.46	$-0.54	$-0.62
Avg Forecast	$-0.14	$-0.13	$-0.14	$-0.16	$-0.09	$-0.18	$-0.28	$-0.28	$-0.30	$-0.33	$-0.30	$-0.28	$-0.29	$-0.38	$-0.39	$-0.40	$-0.42	$-0.39	$-0.42	$-0.38	$-0.35	$-0.36	$-0.41	$-0.33	$-0.45	$-0.44	$-0.46	$-0.40	$-0.15
High Forecast	$-0.14	$-0.13	$-0.14	$-0.14	$-0.06	$-0.18	$-0.28	$-0.28	$-0.27	$-0.33	$-0.30	$-0.28	$-0.29	$-0.38	$-0.39	$-0.40	$-0.42	$-0.39	$-0.42	$-0.38	$-0.35	$-0.36	$-0.41	$-0.33	$-0.45	$-0.44	$-0.46	$-0.40	$-0.12
Low Forecast	$-0.14	$-0.13	$-0.14	$-0.18	$-0.11	$-0.18	$-0.28	$-0.28	$-0.35	$-0.33	$-0.30	$-0.28	$-0.29	$-0.38	$-0.39	$-0.40	$-0.42	$-0.39	$-0.42	$-0.38	$-0.35	$-0.36	$-0.41	$-0.33	$-0.45	$-0.44	$-0.46	$-0.40	$-0.18
Surprise %	-	-	-	-	-	-	-	-	-	-	0.95%	1.08%	1.39%	0.82%	0.97%	1.09%	0.64%	1.06%	0.79%	1.08%	1.07%	0.93%	0.94%	1.44%	0.83%	0.70%	1.00%	1.35%	4.13%

According to undefined Wall Street analysts, Cue Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CUE previous annual EPS of $NaN (undefined).

Cue Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	$0.29	$14.00	4727.59%	Buy
DRMA	Dermata Therapeutics	$1.10	$6.00	445.45%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
INMB	INmune Bio	$4.98	$22.00	341.77%	Buy
TCRX	TScan Therapeutics	$2.97	$12.00	304.04%	Buy
PYPD	PolyPid	$2.50	$10.00	300.00%	Buy
COYA	Coya Therapeutics	$5.61	$18.00	220.86%	Buy
CUE	Cue Biopharma	$1.06	$3.00	183.02%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
FENC	Fennec Pharmaceuticals	$6.07	$15.75	159.47%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
ANIX	Anixa Biosciences	$2.74	$3.50	27.74%	Buy

CUE Forecast FAQ

Is Cue Biopharma a good buy?

Yes, according to 3 Wall Street analysts, Cue Biopharma (CUE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CUE's total ratings.

What is CUE's price target?

Cue Biopharma (CUE) average price target is $3 with a range of $2 to $4, implying a 197.03% from its last price of $1.01. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cue Biopharma stock go up soon?

According to Wall Street analysts' prediction for CUE stock, the company can go up by 197.03% (from the last price of $1.01 to the average price target of $3), up by 296.04% based on the highest stock price target, and up by 98.02% based on the lowest stock price target.

Can Cue Biopharma stock reach $2?

CUE's average twelve months analyst stock price target of $3 supports the claim that Cue Biopharma can reach $2 in the near future.

What are Cue Biopharma's analysts' financial forecasts?

Cue Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.72M (high $6.26M, low $5.04M), average EBITDA is $-5.72M (high $-5.038M, low $-6.26M), average net income is $-42.546M (high $-41.445M, low $-43.923M), average SG&A $29.18M (high $31.94M, low $25.7M), and average EPS is $-0.831 (high $-0.809, low $-0.857). CUE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.59M (high $6.59M, low $6.59M), average EBITDA is $-6.592M (high $-6.592M, low $-6.592M), average net income is $-29.03M (high $-27.96M, low $-30.101M), average SG&A $33.63M (high $33.63M, low $33.63M), and average EPS is $-0.567 (high $-0.546, low $-0.588).

Did the CUE's actual financial results beat the analysts' financial forecasts?

Based on Cue Biopharma's last annual report (Dec 2022), the company's revenue was $1.25M, which missed the average analysts forecast of $4.8M by -74.07%. Apple's EBITDA was $-50.767M, beating the average prediction of $-15.352M by 230.69%. The company's net income was $-52.796M, missing the average estimation of $-67.504M by -21.79%. Apple's SG&A was $16.17M, missing the average forecast of $24M by -32.64%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.464 by 1.08%. In terms of the last quarterly report (Jun 2023), Cue Biopharma's revenue was $1.38M, beating the average analysts' forecast of $907.5K by 52.29%. The company's EBITDA was $-12.104M, beating the average prediction of $-908K by 1233.77%. Cue Biopharma's net income was $-13.185M, missing the average estimation of $-15.625M by -15.62%. The company's SG&A was $4.25M, missing the average forecast of $4.63M by -8.23%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-0.305 by -4.92%